Thyroid Function in Liver Cirrhosis: Is it Affected?
1 other identifier
observational
25
1 country
1
Brief Summary
In patient with liver cirrhosis ,thyroid functions are largely affected in our study we studied the changes in thyroid functions in patients with liver cirrhosis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 18, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 18, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 18, 2022
CompletedFirst Submitted
Initial submission to the registry
January 27, 2022
CompletedFirst Posted
Study publicly available on registry
February 22, 2022
CompletedFebruary 22, 2022
February 1, 2022
8 months
January 27, 2022
February 21, 2022
Conditions
Outcome Measures
Primary Outcomes (3)
thyroid stimulating hormone
TSH in μIU/ml
1 year
Triiodothyronine
T3 in pg/ml
1 year
thyroxine
T4 in ng/dl
1 year
Study Arms (2)
patients with liver cirrhosis
control group
Interventions
laboratory tests
Eligibility Criteria
* Sex: both * Age:18-80 years. * Known and established cases of cirrhosis liver by clinical, radiological (ultrasound abdomen), and biochemical study. * Patients who were willing to part of study after consent. * Control - Apparently healthy age- and sex-matched individuals between 18 and 80 years * Age: below 18 or above 80 years old. * Known cases of thyroid disorder without liver cirrhosis. * Patient with history of organ failure, cancer, radio or chemotherapy and individual with active infection such as bone and muscle disease, cardiac, pancreatic (diabetes), chronic kidney disease, nephrotic syndrome. * Patient using drugs that interfere with thyroid metabolism such as levothyroxine, propylthiouracil, carbimazole, iodine, amiodarone, and beta-blockers.
You may qualify if:
- Sex: both
- Age:18-80 years.
- Known and established cases of cirrhosis liver by clinical, radiological (ultrasound abdomen), and biochemical study.
- Patients who were willing to part of study after consent.
- Control - Apparently healthy age- and sex-matched individuals between 18 and 80 years.
You may not qualify if:
- Age: below 18 or above 80 years old.
- Known cases of thyroid disorder without liver cirrhosis.
- Patient with history of organ failure, cancer, radio or chemotherapy and individual with active infection such as bone and muscle disease, cardiac, pancreatic (diabetes), chronic kidney disease, nephrotic syndrome.
- Patient using drugs that interfere with thyroid metabolism such as levothyroxine, propylthiouracil, carbimazole, iodine, amiodarone, and beta-blockers.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
MansouraU
Al Mansurah, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
January 27, 2022
First Posted
February 22, 2022
Study Start
May 18, 2021
Primary Completion
January 18, 2022
Study Completion
January 18, 2022
Last Updated
February 22, 2022
Record last verified: 2022-02
Data Sharing
- IPD Sharing
- Will not share